Búsqueda | Biblioteca Virtual en Salud Odontología. Uruguay

1.

Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study.

Silfverberg, Thomas; Zjukovskaja, Christina; Ljungman, Per; Nahimi, Adjmal; Ahlstrand, Erik; Dreimane, Arta; Einarsdottir, Sigrun; Fagius, Jan; Iacobaeus, Ellen; Hägglund, Hans; Lange, Niclas; Lenhoff, Stig; Lycke, Jan; Mellergård, Johan; Piehl, Fredrik; Svenningsson, Anders; Tolf, Andreas; Cherif, Honar; Carlson, Kristina; Burman, Joachim.

J Neurol Neurosurg Psychiatry ; 95(2): 125-133, 2024 Jan 11.

Artículo en Inglés | MEDLINE | ID: mdl-37748927

2.

Early-onset hereditary isolated non-neurogenic orthostatic hypotension in a Swedish family.

Fagius, Jan; Klar, Joakim; Dahl, Niklas.

Clin Auton Res ; 33(4): 421-432, 2023 08.

Artículo en Inglés | MEDLINE | ID: mdl-37460866

3.

Sustained remission in multiple sclerosis after hematopoietic stem cell transplantation.

Tolf, Andreas; Fagius, Jan; Carlson, Kristina; Åkerfeldt, Torbjörn; Granberg, Tobias; Larsson, Elna-Marie; Burman, Joachim.

Acta Neurol Scand ; 140(5): 320-327, 2019 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-31297793

4.

Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.

Burt, Richard K; Balabanov, Roumen; Burman, Joachim; Sharrack, Basil; Snowden, John A; Oliveira, Maria Carolina; Fagius, Jan; Rose, John; Nelson, Flavia; Barreira, Amilton Antunes; Carlson, Kristina; Han, Xiaoqiang; Moraes, Daniela; Morgan, Amy; Quigley, Kathleen; Yaung, Kimberly; Buckley, Regan; Alldredge, Carri; Clendenan, Allison; Calvario, Michelle A; Henry, Jacquelyn; Jovanovic, Borko; Helenowski, Irene B.

JAMA ; 321(2): 165-174, 2019 01 15.

Artículo en Inglés | MEDLINE | ID: mdl-30644983

5.

Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience.

Burman, Joachim; Iacobaeus, Ellen; Svenningsson, Anders; Lycke, Jan; Gunnarsson, Martin; Nilsson, Petra; Vrethem, Magnus; Fredrikson, Sten; Martin, Claes; Sandstedt, Anna; Uggla, Bertil; Lenhoff, Stig; Johansson, Jan-Erik; Isaksson, Cecilia; Hägglund, Hans; Carlson, Kristina; Fagius, Jan.

J Neurol Neurosurg Psychiatry ; 85(10): 1116-21, 2014 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-24554104

6.

T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis.

Burman, Joachim; Fransson, Moa; Tötterman, Thomas H; Fagius, Jan; Mangsbo, Sara M; Loskog, Angelica S I.

Immunology ; 140(2): 211-9, 2013 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-23721329

7.

High resting level and weak response of baroreflex-governed sympathetic outflow in amyotrophic lateral sclerosis.

Nygren, Ingela; Fagius, Jan.

Muscle Nerve ; 43(3): 432-40, 2011 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-21305564

8.

Strong potential for baroreflex-governed sympathetic outflow revealed during nausea.

Fagius, Jan; Nygren, Ingela.

Clin Auton Res ; 20(6): 371-4, 2010 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-20680386

9.

The T-cell pool is anergized in patients with multiple sclerosis in remission.

Fransson, Moa E; Liljenfeldt, Lina S E; Fagius, Jan; Tötterman, Thomas H; Loskog, Angelica S I.

Immunology ; 126(1): 92-101, 2009 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-18624727

10.

Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab.

Fagius, Jan; Feresiadou, Amalia; Larsson, Elna-Marie; Burman, Joachim.

Mult Scler Relat Disord ; 12: 82-87, 2017 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-28283113

11.

Sympathetic nerve activity to amputated lower leg in humans. Evidence of altered skin vasoconstrictor discharge.

Fagius, Jan; Nordin, Magnus; Wall, Magnus.

Pain ; 98(1-2): 37-45, 2002 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-12098615

12.

The cerebrospinal fluid cytokine signature of multiple sclerosis: a homogenous response that does not conform to the Th1/Th2/Th17 convention.

Burman, Joachim; Svensson, Emma; Fransson, Moa; Loskog, Angelica S I; Zetterberg, Henrik; Raininko, Raili; Svenningsson, Anders; Fagius, Jan; Mangsbo, Sara M.

J Neuroimmunol ; 277(1-2): 153-9, 2014 Dec 15.

Artículo en Inglés | MEDLINE | ID: mdl-25457841

13.

Tack för erbjudandet, men nej tack...

Fagius, Jan.

Lakartidningen ; 1152018 04 24.

Artículo en Sueco | MEDLINE | ID: mdl-29688564

14.

[Hematopoietic stem cell transplantation in MS. Justified, and if so, when?]. / Blodstamcells-transplantation vid MS. Motiverat och i så fall när?

Fagius, Jan; Oberg, Gunnar.

Lakartidningen ; 103(9): 640-2, 2006.

Artículo en Sueco | MEDLINE | ID: mdl-16583539

15.

[TGA: Clinical assessment is sufficient in the investigation!]. / TGA: utredningen kan stanna vid klinisk bedömning!

Fagius, Jan.

Lakartidningen ; 102(28-29): 2093; author reply 2093, 2005.

Artículo en Sueco | MEDLINE | ID: mdl-16097186

16.

T regulatory cells lacking CD25 are increased in MS during relapse.

Fransson, Moa; Burman, Joachim; Lindqvist, Camilla; Atterby, Christina; Fagius, Jan; Loskog, Angelica.

Autoimmunity ; 43(8): 590-7, 2010 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-20370571

17.

[Disease-modifying treatment of MS--progress with complications]. / Sjukdomsmodifierande behandling mot MS--framsteg med komplikationer.

Fagius, Jan.

Lakartidningen ; 100(13): 1164, 1167-8, 2003 Mar 27.

Artículo en Sueco | MEDLINE | ID: mdl-12705166

18.

Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial.

Killestein, Joep; Olsson, Tomas; Wallström, Erik; Svenningsson, Anders; Khademi, Mohsen; Blumhardt, Lance D; Fagius, Jan; Hillert, Jan; Landtblom, Anne-Marie; Edenius, Charlotte; Arfors, Leopold; Barkhof, Frederik; Polman, Chris H.

Ann Neurol ; 51(4): 467-74, 2002 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-11921052

Biblioteca Virtual en Salud Odontología. Uruguay

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study.

Early-onset hereditary isolated non-neurogenic orthostatic hypotension in a Swedish family.

Sustained remission in multiple sclerosis after hematopoietic stem cell transplantation.

Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.

Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience.

T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis.

High resting level and weak response of baroreflex-governed sympathetic outflow in amyotrophic lateral sclerosis.

Strong potential for baroreflex-governed sympathetic outflow revealed during nausea.

The T-cell pool is anergized in patients with multiple sclerosis in remission.

Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab.

Sympathetic nerve activity to amputated lower leg in humans. Evidence of altered skin vasoconstrictor discharge.

The cerebrospinal fluid cytokine signature of multiple sclerosis: a homogenous response that does not conform to the Th1/Th2/Th17 convention.

Tack för erbjudandet, men nej tack...

[Hematopoietic stem cell transplantation in MS. Justified, and if so, when?]. / Blodstamcells-transplantation vid MS. Motiverat och i så fall när?

[TGA: Clinical assessment is sufficient in the investigation!]. / TGA: utredningen kan stanna vid klinisk bedömning!

T regulatory cells lacking CD25 are increased in MS during relapse.

[Disease-modifying treatment of MS--progress with complications]. / Sjukdomsmodifierande behandling mot MS--framsteg med komplikationer.

Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial.